UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 561,894 Shares of R1 RCM Inc. (NASDAQ:RCM)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in shares of R1 RCM Inc. (NASDAQ:RCM) by 53.1% in the third quarter, HoldingsChannel.com reports. The firm owned 497,273 shares of the healthcare provider’s stock after selling 561,894 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in R1 RCM were worth $7,046,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in RCM. Alpine Associates Management Inc. bought a new stake in shares of R1 RCM in the 3rd quarter valued at $25,680,000. Tokio Marine Asset Management Co. Ltd. acquired a new position in R1 RCM in the third quarter valued at $11,986,000. ING Groep NV bought a new position in shares of R1 RCM in the 3rd quarter worth about $2,519,000. Wolverine Asset Management LLC bought a new position in shares of R1 RCM in the 3rd quarter worth about $2,335,000. Finally, Bardin Hill Management Partners LP raised its position in shares of R1 RCM by 98.7% in the 2nd quarter. Bardin Hill Management Partners LP now owns 525,211 shares of the healthcare provider’s stock worth $6,597,000 after acquiring an additional 260,891 shares in the last quarter. Institutional investors and hedge funds own 61.10% of the company’s stock.

R1 RCM Stock Up 0.1 %

Shares of NASDAQ RCM opened at $14.31 on Tuesday. R1 RCM Inc. has a 1 year low of $8.87 and a 1 year high of $15.12. The stock has a market capitalization of $6.04 billion, a P/E ratio of -95.39 and a beta of 0.84. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.79 and a quick ratio of 1.79. The company has a 50-day moving average price of $14.26 and a 200-day moving average price of $13.63.

R1 RCM (NASDAQ:RCM) last issued its quarterly earnings data on Tuesday, November 5th. The healthcare provider reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.04). The company had revenue of $656.80 million during the quarter, compared to analysts’ expectations of $640.93 million. R1 RCM had a negative return on equity of 2.18% and a negative net margin of 2.48%. R1 RCM’s revenue was up 14.7% compared to the same quarter last year. On average, equities research analysts forecast that R1 RCM Inc. will post -0.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $14.30 target price on shares of R1 RCM in a research note on Friday, October 4th. Thirteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $15.41.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.